| Accession Number: | 0001209191-21-055954 |
| Date: | 2021-09-13 |
| Issuer: | SORRENTO THERAPEUTICS, INC. (SRNE) |
| Original Submission Date: |
JANDA KIM
C/O SORRENTO THERAPEUTICS, INC.
4955 DIRECTORS PLACE
SAN DIEGO, CA 92121
| Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
|---|---|---|---|---|---|---|---|---|---|
| COMMON STOCK | 2021-09-13 | M | 8,000 | a | $3.50 | 11,000 | direct | ||
| COMMON STOCK | 2021-09-13 | S | 8,000 | d | $8.04 | 3,000 | direct |
| Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NON-QUALIFIED STOCK OPTION | 3.5 | 2021-09-13 | deemed execution date | M | 8,000 (d) | 2021-09-28 | common stock 8,000 | $3.50 | 0 | direct |
| ID | footnote |
|---|---|
| f1 | this transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person. |
| f2 | the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $7.84 to $8.23, inclusive. the reporting person undertakes to provide upon request by the staff of the securities and exchange commission, the issuer or a security holder of the issuer full information regarding the number of shares purchased or sold at each separate price. |
| f3 | 25% of the shares subject to the option vested on september 28, 2012, and 1/48th of the shares subject to the option vested monthly thereafter. |
